表纸
市场调查报告书

神经退化性疾病的新治疗药物:第I部分 - 阿兹海默症和帕金森氏症的新标靶治疗策略技术

Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases

出版商 Frost & Sullivan 商品编码 910112
出版日期 内容资讯 英文 110 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
神经退化性疾病的新治疗药物:第I部分 - 阿兹海默症和帕金森氏症的新标靶治疗策略技术 Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases
出版日期: 2019年08月23日内容资讯: 英文 110 Pages
简介

本报告研究阿兹海默症和帕金森氏症的新治疗药物趋势,分析疾病背景和概要、新治疗药物种类和概要、药剂开发现况和课题、市场潜力、企业和企业间行动、影响市场的各种因素等情报。

第1章 摘要整理

第2章 神经退化性疾病:技术环境和趋势

  • 现况和课题
  • 多因性发病
  • 并行触发因素
  • 新兴治疗药物
  • 补助医疗

第3章 神经退化性疾病的新治疗法

  • 治疗和诊断解决方案:PROTAC
  • 神经退化性治疗:标靶蛋白质配位体
  • 治疗和诊断解决方案:类□
  • 神经退化性治疗:类□方法
  • 神经退化性治疗:聚集抑制剂
  • 神经退化性治疗:细胞信号传达调节
  • 神经退化性治疗:仿生神经保护剂
  • 神经退化性治疗:炎症调节剂
  • 神经退化性治疗:影像诊断生物标记
  • 神经退化性治疗:类□介入
  • 治疗和诊断解决方案:干细胞/基因疗法
  • 神经退化性治疗:细胞疗法的开发
  • 治疗和诊断解决方案:肠道微生物群
  • 神经退化性治疗:肠道微生物群介入
  • 治疗和诊断解决方案:奈米技术、前驱药、Codrug
  • 治疗和诊断解决方案:大麻二酚
  • 神经退化性治疗:预防和管理

第4章 技术现况:概要和评估

  • 神经退化性临床前模型:需求和复杂性
  • 神经退化性模型的缺点:阿兹海默症
  • 神经退化性模型的缺点:帕金森氏症
  • 治疗技术现况
  • 阿兹海默症治疗药物开发情况
  • 帕金森氏症治疗药物开发情况

第5章 技术雷达智能解决方案

  • 缓和治疗到未来策略
  • 新治疗策略和初步成果
  • 推动临床试验的单株抗体
  • 强化自噬的药理制剂
  • 阿兹海默症:具潜力的候选分子药物
  • 帕金森氏症:主要企业

第6章 市场潜力和技术导入

  • 神经退化性疾病市场的潜力
  • 对整体环境的影响因素
  • 产业合作:SWOT分析
  • 神经退化性疾病的合作框架
  • 概要:商业合作和技术能力
  • 透过合作创制确定目标

第7章 商业环境和智慧财产权

  • 对业务开发的实用影响
  • 对业务和流程的影响
  • 技术转移评估

第8章 附录

  • 药剂PIPELINE:阿兹海默症
  • 药剂PIPELINE:帕金森氏症

第9章 产业联络资讯

  • 主要产业影响者
  • 免责声明
目录
Product Code: D8BB

Novel Targeted Therapeutic Strategies Technologies Around Neurodegenerative Disorders - From Palliative to Future Interventions

At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose neurodegenerative diseases.

At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.

The most common denominator among neurodegenerative diseases, in addition to nerve cell loss is inflammation. Although, a series of mutant genes and environmental toxins are related to neurodegenerative disorders, the causal mechanisms remain poorly understood.

Neurodegenerative diseases can be defined as multifactorial debilitating disorders of the nervous system. Overall, neurodegenerative diseases affect approximately 30 million individuals worldwide, according to the World Health Organization (WHO).

Factors Contributing to Neurodegenerative Diseases

The factors contributing to the onset of neurodegenerative diseases are multiple. Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) diseases are well-established as the consequence of misfolding and dysfunctional trafficking of proteins. However, other factors including mitochondrial dysfunction, oxidative stress, aging, and environmental issues are deeply associated with the onset of neurodegeneration.

Molecular Mechanisms Underlying Neurodegeneration

Although all these factors have been demonstrated to significantly contribute to the etiology of common neurodegenerative diseases, some molecular mechanisms underlying neurodegeneration remain unveiled.

Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best suited therapies.

  • Some Multifactorial Conditions to Watch
  • Abnormal protein dynamics
  • Defective protein degradation and aggregation
  • Oxidative stress
  • Free radical formation
  • Impaired bioenergetics
  • Mitochondrial dysfunction
  • Exposure to toxic metals and pesticides
  • Others
  • Coverage of Neurodegenerative Diseases Technologies

This research service, ‘Emerging Therapeutics for Neurodegenerative Diseases', focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.

The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high performance style, while getting market acceptance and achieving market leadership by translating technology innovation to market competitiveness

The study covers the following topics:

  • Technology roadmap, trends, capabilities, and applications targeted
  • Stakeholder activities, influence, industry initiatives, investment environment, and funding support
  • Regional and global regulation landscape and standardization approaches for tackling challenges
  • Technology benchmarking for smart decisions

An appendix is included, comprising lists of major industry influencers found in the field.

Table of Contents

1.0. Executive Summary

  • 1.1. Facts and Findings: Neurodegenerative Diseases
  • 1.2. Research Focus: Neurodegenerative Diseases
  • 1.3. Research Scope: Foreseeing Challenges and Solutions
  • 1.4. Analysis Framework: Frost & Sullivan's Core Value
  • 1.5. Research Methodology

2.0. Technology Landscape and Trends

  • 2.1. Neurodegenerative Diseases: Facts and Challenges
  • 2.2. Neurodegenerative Diseases: Multifactorial Onset
  • 2.3. Neurodegenerative Diseases: Concurrent Triggering Factors
  • 2.4. Neurodegenerative Diseases: Emerging Therapies
  • 2.5. Neurodegenerative Diseases: Complementary Therapies

3.0. Emerging Therapies to Address Neurodegeneration

  • 3.1. Therapeutic and Diagnostic Solutions: PROTACs
  • 3.2. Neurodegenerative Therapies: Targeting Protein Ligands
  • 3.3. Therapeutic and Diagnostic Solutions: Peptoids
  • 3.4. Neurodegenerative Therapies: Five Peptoid Approaches
  • 3.5. Neurodegenerative Therapies: Aggregation Inhibitors
  • 3.6. Neurodegenerative Therapies: Cell Signaling Modulators
  • 3.7. Neurodegenerative Therapies: Biomimetic Neuroprotectors
  • 3.8. Neurodegenerative Therapies: Inflammation Regulators
  • 3.9. Neurodegenerative Therapies: Imaging Diagnostics Biomarkers
  • 3.10. Neurodegenerative Therapies: Summary of Peptoid Interventions
  • 3.11. Therapeutic and Diagnostic Solutions: Stem Cell/Gene Therapies
  • 3.12. Neurodegenerative Therapies: Cell Therapy Developments
  • 3.13. Therapeutic and Diagnostic Solutions: Gut Microbiome
  • 3.14. Neurodegenerative Therapies: Gut Microbiome Interventions
  • 3.15. Therapeutic and Diagnostic Solutions: Nanotech, Prodrug, and Codrug
  • 3.16. Therapeutic and Diagnostic Solutions: Cannabidiols
  • 3.17. Neurodegenerative Therapies: Prevention and Management

4.0. Technology Status Review and Assessment

  • 4.1. Neurodegenerative Preclinical Models: Needs and Complexities
  • 4.2. Neurodegenerative Models' Pitfalls: Alzheimer's Disease
  • 4.3. Neurodegenerative Models' Pitfalls: Parkinson's Disease
  • 4.4. Present Status of Therapeutics Technology
  • 4.5. Alzheimer's Disease Drug Development Status
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.5. Alzheimer's Disease Drug Development Status (continued)
  • 4.6. Parkinson's Disease Drug Development Status

5.0. Technology Radar Intelligent Solutions

  • 5.1. From Palliative Treatment to Future Strategies
  • 5.2. New Treatment Strategies and Preliminary Outcomes
  • 5.2. New Treatment Strategies and Preliminary Outcomes (continued)
  • 5.3. Monoclonal Antibodies Advancing Clinical Trials
  • 5.4. Pharmacological Agents Enhancing Autophagy
  • 5.5. Top Promising Candidates for Alzheimer's Disease
  • 5.6. Parkinson's Disease Top Companies

6.0. Market Potential and Technology Adoption

  • 6.1. Neurodegenerative Diseases Market Potential
  • 6.2. Overall Environmental Impact Factors
  • 6.3. Best-fit Industry Partnerships: SWOT Analysis
  • 6.4. Collaborative Framework for Neurodegenerative Diseases
  • 6.5. Overview of Business Partnerships and Technology Capabilities
  • 6.6. Key Aspects to Target through Collaborative Initiatives

7.0. Business Landscape and Intellectual Property Analysis

  • 7.1. Actionable Impact on Business Development
  • 7.2. Repercussions on Businesses and Processes
  • 7.3. Technology Transfer Assessment

8.0. Appendix

  • 8.1. Alzheimer's Disease Drug Pipeline
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.1. Alzheimer's Disease Drug Pipeline (continued)
  • 8.2. Parkinson's Disease Drug Pipeline
  • 8.2. Parkinson's Disease Drug Pipeline (continued)

9.0. Key Industry Contacts

  • 9.1. Key Industry Influencers
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • 9.1. Key Industry Influencers (continued)
  • Legal Disclaimer
Back to Top